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ABSTRACT 
The prevalence of type 2 diabetes is increasing worldwide and is about to reach 
epidemic proportions. The disease is often associated with dyslipidemia, which is 
characterized by an atherogenic lipoprotein profile including elevated serum 
triacylglycerol levels, low high-density lipoprotein levels and high levels of small 
low-density lipoproteins. Several large clinical studies have shown that this 
change in serum lipoprotein profile constitutes a major cardiovascular risk 
factor, but the molecular mechanisms are still not completely understood. It has 
been proposed that intrinsic properties of the particles, such as protein and lipid 
composition, might be responsible for the increased risk, mediated through an 
increased accumulation of lipoproteins in the artery wall, leading to 
atherosclerosis. The primary aim of this thesis was to isolate and, with a 
lipidomics approach, characterize the atherogenic lipoproteins from patients 
with type 2 diabetes. A secondary aim was to link compositional changes to 
atherosclerotic processes in vitro.    
Initially, an ultracentrifugational method was developed for the isolation of 
lipoproteins at physiological settings. Then, in order to make a comprehensive 
lipid characterization of the lipoproteins, an analytical platform for lipidomics 
analyses was established. This platform consists of a normal-phase HPLC system 
with an evaporative light scattering detector that is used in combination with a 
hybrid quadrupole time-of-flight instrument, equipped with a chip-based 
nanoelectrospray interface.  
By using this platform, atherogenic lipoproteins from patients participating in 
two major studies were characterized. The results revealed several alterations in 
the lipid and protein composition of the atherogenic lipoproteins isolated from 
patients with type 2 diabetes. Several of these alterations could, by the use of 
different in vitro systems, be linked mechanistically to proatherogenic processes 
such as lipoprotein retention and tissue inflammation. We also showed that 
changes in lipoprotein lipid composition were mainly associated with 
dyslipidemia. 
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“If we knew what it was we were doing,  
it would not be called research, would it?” 
 
Albert Einstein 
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BIOLOGICAL BACKGROUND 
Cardiovascular disease 
Cardiovascular disease (CVD) is a group of disorders of the heart and blood 
vessels and includes coronary heart disease (CHD) (e.g. myocardial infarction 
and angina pectoris), cerebrovascular disease (e.g. stroke) and peripheral artery 
disease. CVD is the number one killer in the world, representing 29% of all global 
deaths 1. The most important behavioral risk factors, responsible for about 80% 
of the coronary heart disease and cerebrovascular disease, are unhealthy diets, 
inactivity and tobacco use 1. The effects of unhealthy diets and inactivity are 
manifested as obesity and type 2 diabetes (T2D), which are also strong 
predictors for cardiovascular disease. These will be discussed below.  
 
Obesity 
“Let me have men around me that are fat…” 
In Shakespeare’s Julius Caesar, the Roman emperor suggests that a high body 
mass correlates with a well-balanced mental disposition. In those days, the 
prevalence of obesity was low and the state not considered a medical risk factor. 
Today obesity is a growing problem about to reach epidemic proportions 2. In a 
recently published report, WHO estimates that about 400 million adults (+15 
years) are obese (BMI≥30) with an additional 1.6 billion people being overweight 
(25<BMI>30) 3. The increased prevalence of obesity and overweight, which to a 
great extent can be explained by the change to a more sedentary lifestyle and the 
constant access to palatable, energy-dense foods, is associated with several 
negative consequences. Not only do obese subjects have an elevated risk of 
mental illness such as depression and anxiety 4, they also have an increased risk 
of premature death 5-7. Much of this increased risk can be explained by the wide 
range of comorbidities associated with obesity including dyslipidemia, T2D, 
hypertension and stroke 8. 
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Type 2 diabetes and insulin resistance 
In parallel to the rise in obesity, the prevalence of T2D is increasing alarmingly. 
According to estimations by the international diabetes federation (IDF), 285 
million people are suffering from the disease, which is thought to increase to 
almost 440 million by the year 2030. This increase will affect all global regions, 
with projected increases ranging from 21% in Europe to 111% in Africa 9. 
Diabetes is a chronic disease that can be divided into two subclasses where type 
1 diabetes is primarily due to autoimmune mediated destruction of the 
pancreatic β-cells, resulting in insulin deficiency. T2D, which constitutes about 
90% of all cases 10, develops over several years and is initiated by an inability of 
the peripheral tissue to pick up glucose from the circulation as a response to the 
insulin signal (insulin resistance). This leads to a compensatory increased 
production of insulin by the pancreatic β-cells and increased levels in the 
circulation. This results in normal, or near-normal, plasma glucose levels, which 
can disguise the pathological condition for years. The period, between the 
appearance of insulin resistance and the onset of type 2 diabetes, is today often 
termed pre-diabetes and is characterized by an impaired glucose tolerance (IGT). 
IGT, which is defined as hyperglycemia (with values intermediate between 
normal and diabetes) following a glucose load, is in itself associated with 
cardiovascular risk and it is estimated that 40% of these subjects will develop 
T2D over 5-10 years 10. The state of diabetes occurs, often as a result of β-cells 
dysfunction, when the pancreas can’t produce sufficient levels of insulin to 
maintain homeostasis. This will lead to a reduced glucose clearance by peripheral 
tissue and increased glucose production by the liver, causing the blood levels to 
rise 11.   
The medical and socioeconomic burden of T2D, which is caused by the associated 
complications, imposes enormous strains on health-care systems. The 
complications are both macro- and microvascular diseases as a consequence of 
accelerated atherogenesis. T2D is the fifth leading cause of death in the US 12 and 
cardiovascular morbidity in patients with T2D is two to four times higher than in 
non-diabetic patients 10. 
 
Metabolic Syndrome 
The metabolic syndrome, also known as “syndrome X” 13, “the insulin resistance 
syndrome” 14 and the “deadly quartet” 15, is a clustering of factors associated with 
an increased risk of CVD and T2D 16-21. The development of the metabolic 
syndrome is driven by obesity and/or insulin resistance and results in 
atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, a 
11
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pro-thrombotic and a pro-inflammatory state, which are all considered core risk 
factors (figure 1). The rational for using the metabolic syndrome as a tool in 
practice is that the accumulated risk for a person displaying several risk factors is 
higher than that of its individual components 17. However, questions have been 
raised to the clinical utility of putting efforts into establishing diagnostic criteria 
for the metabolic syndrome 22-23. 
 
 
 
 
 
 
Figure 1. Obesity and T2D are the driving forces behind the development of the metabolic 
syndrome, which is associated with several risk factors leading to atherosclerosis and 
premature death.  
 
 
Several definitions of the metabolic syndrome are available. The most commonly 
used are from WHO 24, the European Group for Study of Insulin Resistance 
(EGIR)25 and the National Cholesterol Education Program’s Adult Treatment 
Panel III (NCEP:ATPIII) 26. To be classified as having the metabolic syndrome 
according to the WHO criteria, which is the definition mostly used in Sweden, the 
patient must have either T2D, impaired glucose tolerance (IGT) or insulin 
resistance and also two (or more) additional risk factors (figure 2). In the US, the 
definition from the NCEP:ATPIII is often used. This definition is similar to the one 
proposed by WHO but doesn’t require the presence of T2D, insulin resistance or 
IGT, thereby making it less “glucose-centric”. 
Despite attempts in recent years to reach an agreement on the definition of the 
metabolic syndrome, it remains difficult to compare the prevalence published for 
different populations. However, a highly consistent finding is that the prevalence 
is strongly age-dependant 27. It has been shown from studies performed in 
several countries, involving different ethnicities, that the prevalence is usually 
lower than 10% for both men and women below 30 years of age 28-30. However, 
for people in the 60-69 age group, the prevalence might be as high as 67% 30.  
Obesity
Insulin Resistance
Metabolic Syndrome
Atherogenic dyslipidemia
Pro-thrombotic stateVascular in�lammation Elevated plasma glucose
Vascular dysfunction Atherosclerosis
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In a study performed in Gothenburg Sweden, the prevalence of the metabolic 
syndrome in 778 elderly (70-year-old) individuals were estimated to be 26% for 
men and 19% for women using the NCTP:ATPIII definition 31. Another study 
performed in the same region, with a cohort consisting of 104 middle aged men, 
showed similar prevalence with, depending on the definition used, 22% or 28% 
of the individuals having the metabolic syndrome 32. 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Inclusion criteria for defining the metabolic syndrome according to the WHO 24. 
Adapted from Zimmet et al.10 
 
 
Atherosclerosis  
Atherosclerosis is a consequence of the metabolic syndrome and the underlying 
cause of most cardiovascular disease including coronary artery disease, ischemic 
gangrene, aortic aneurysms and many cases of heart failure and stroke. It has 
been estimated that atherosclerotic cardiovascular disease (ASCVD) (CVD caused 
by atherosclerosis) is responsible for 50% all deaths in Europe 33-34. Parts of the 
very complex pathogenesis of atherosclerosis will be described in the following 
sections. 
 
Hyperuricaemia
Hypercoagulablity
Hyperleptinaemia
Insuline Resistance
Type 2 Diabets
Impaired Glucose Tolerance
Hypertension
Obesity
Hypertriglyceridaemia
Low HDL
Microalbuminuria
At least 1 + At least 2 Metabolic 
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Not required for definition, 
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The atherosclerotic plaque 
Atherosclerotic lesions, termed atheromas or atherosclerotic plaques, are 
typically present as asymmetric focal thickenings of the inner-most layer of the 
artery, the intima. The atheroma is preceded chronologically by so-called fatty 
streaks. These can be present already in early life, even in the arteries of small 
children 35-36. Atherosclerosis is a silent and slowly progressing disease and the 
transformation of the fatty streaks into advanced atheromas often takes many 
years 37. The advanced atheroma is structurally more complex than the fatty 
streak and has a core rich in macrophage foam cells, dead cells, and extracellular 
lipid droplets. The core is often surrounded by a cap of smooth muscle cells and 
collagen-rich matrix 34. During the progression of atherosclerosis, inflammation 
plays a major role with inflammatory cells such as T-cells, dendritic cells and 
mast cell present during all stages of atherogenesis 38.  
As the atheroma continues to grow, the narrowing of the arteries will eventually 
lead to a clinical event. Partial occlusion of an artery leads to ischemia of the 
supported organ and might lead to angina pectoris (heart) or intermittent 
claudication of the legs. Furthermore, some plaques that are highly inflamed and 
have a thin fibrous cap might rupture. This might cause total occlusion of the 
blood flow leading to myocardial infarction or stroke 39-40.  
 
Lipoproteins 
Lipoproteins are spherical protein-coated lipid particles that play important 
roles in both the initiation and progression of atherosclerosis. Their main 
function is to enable the transport of hydrophobic lipids, such as cholesterol 
esters and triglycerides (and also vitamins), throughout the circulatory system. 
The hydrophobic lipids are kept in the centre of the particle and are surrounded 
by a monolayer of amphipathic phospholipids with their hydrophobic regions 
(fatty acids) turned inwards and their polar head groups facing the aqueous 
environment (figure 3). The composition and size of the lipoprotein particle can 
vary and the lipoproteins are often classified into subgroups depending on their 
density (table 1), which will be determined by the lipid/protein ratio. Since the 
size of the particle is correlated to the amount of lipid, this means that larger 
particles will have a higher lipid/protein ratio and thus lower density. 
Chylomicrons (CMs) are large triacylglycerol-rich particles secreted into the 
intestine and function as carriers of dietary lipids. In the circulation, the 
metabolism of chylomicrons occurs mainly through the action of lipoprotein 
lipase (LPL) (figure 4). This enzyme hydrolyzes the triacylglycerols into fatty 
acids and glycerol and produces smaller chylomicron remnants, which eventually  
14
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will be removed from the circulation by the liver. Very-low density lipoprotein 
(VLDL) consists of large triacylglycerol-rich particles secreted by the liver. As 
VLDL is metabolized in the circulation, mainly through the action of LPL and 
hepatic lipase (HL), the particles are gradually deprived of their lipid 
constituents and reduced in size. This results in the generation of intermediate- 
density lipoprotein (IDL) and then to even smaller low-density lipoprotein (LDL). 
This process of delivery of lipids to peripheral tissue is often referred to as 
“forward lipid transport”.  
 
 
 
 
 
 
 
 
Figure 3. Structure of a lipoprotein particle with a core of hydrophobic lipids surrounded by 
an outer monolayer of amphipathic lipids, with their hydrophobic tails turned inward and 
the polar heads outward to the aqueous environment. 
Table 1. Characteristics of different lipoprotein classes. 
 CM VLDL LDL HDL 
Density (g/ml) <0.95 0.95-1.019 1.019 -1.063 1.063-1.210 
Diameter (nm) 80-100 25-80 20-25 8-13 
Total lipid (wt %) 98-99 90-92 75-80 40-48 
     
Lipid composition  
(wt % of total lipids) 
    
CE 2-4 15-23 47-51 24-45 
TAG 81-89 50-58 7-11 6-7 
FC 1-3 4-9 10-12 6-8 
PL 7-9 19-21 28-30 42-51 
CE, cholesteryl esters; TAG, triacylglycerols; PL, phospholipids; FC, free cholesterol. 
Adapted from 41 and 42. In the table above, IDL is included in the VLDL class.  
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Figure 4. Both chylomicrons and VLDL are metabolized by lipases in the circulation resulting 
in smaller lipid deprived particles that are removed from the circulation by the liver through 
receptor-, and non-receptor-mediated uptake.  
?
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smaller apoCs. Apolipoproteins play several important roles in the metabolism of 
lipoproteins as they are crucial for the interaction of the lipoprotein particles 
with enzymes, transfer proteins and cell surface receptors.  
 
Apolipoprotein B (apoB) comes in two variants. ApoB100, which is one of the 
largest human proteins, consisting of 4536 amino acids, is the main protein on 
the VLDL particle. A truncated version consisting of the amino-terminal end of 
the apoB100 molecule is secreted attached to the chylomicron particle in the 
intestine. This molecule is called apoB48 since the size of the protein is 48% of 
the apoB100 molecule. The apoB molecule, which always exists in one copy per 
particle, is a non-exchanging lipoprotein. This means that it will stay attached to 
the lipoprotein during its time in the circulation. The apoB molecule is important 
for the uptake and removal of lipoproteins via the LDL-receptor. If the sequence 
involved in the receptor recognition is altered, as is the case in familial defective 
apoB100 (FDB), this will result in a reduced clearance of these particles, with 
hypercholesterolemia and premature atherosclerosis as a consequence 53.   
 
Apolipoprotein E was first described as a lipoprotein constituent of VLDL 54 but 
is now recognized as a major component of several classes of plasma lipoproteins 
55-57. The majority of apoE found in plasma is produced by the liver, with 20-40% 
being derived from extra-hepatic sources such as brain, muscle and also 
macrophages 58-59. ApoE plays important roles in the circulation by facilitating 
the uptake and degradation of lipoproteins through its interaction with the LDL-
receptor 60-61. 
 
Apolipoprotein CIII is a small protein (8.8 kDa) produced mainly by the liver 
and to a lesser extent by the intestine 62. It is present in three isoforms that are 
termed apoCIII0, apoCIII1 and apoCIII2 depending on the number of sialic acid 
molecules (0-2) terminating the oligosaccharidic portion of the protein 63. 
ApoCIII has been shown to inhibit lipolysis of lipoproteins by LPL and also delay 
the removal of apoB-containing lipoproteins by the hepatic LDL-receptor 64-65. 
Both of these mechanisms leads to hypertriglyceridemia and the role of apoCIII 
in the development of dyslipidemia and atherosclerosis will be discussed 
separately.  
 
Apolipoprotein AI (apoAI) is the most abundant protein on HDL. ApoAI is a 28 
kDa protein that can be present in several copies on the HDL surface. ApoAI is an 
exchangeable apolipoprotein. This means that it is more loosely bound to the 
lipoprotein surface and can therefore be transferred between lipoproteins . It is 
also capability of acquiring lipids while in the circulation. In this aspect, apoAI is 
crucial, both in allowing the transfer of cholesterol and phospholipids from 
peripheral tissues to nascent, discoidal HDL, and also for activation of lecithin-
cholesteryl acyl transferase (LCAT). This enzyme is responsible for cholesterol 
esterification and maturation of HDL 66-68. 
17
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Atherogenic dyslipidemia 
The state of dyslipidemia often observed in subjects with T2D and the metabolic 
syndrome is characterized by the so called lipid triad 69. This involves high levels 
of plasma triacylglycerols, low levels of HDL and the appearance of small dense 
LDL (sdLDL). This state, which often precedes T2D by several years, is associated 
with an increased risk of developing atherosclerosis and some of the mechanisms 
behind will be described below. 
 
The lipid triad 
An important driving force, generating all the features of atherogenic 
dyslipidemia described above, is the increased secretion of triacylglycerol-rich 
VLDL particles from the liver (figure 5). The secretion is dependent on the 
availability of triacylglycerol for VLDL particle formation. There are three major 
sources affecting the level of triacylglycerol in the liver:  (i) fatty acids retrieved 
from the circulation, (ii) uptake of chylomicron and VLDL remnants through 
hepatic receptors, and (iii) de novo lipogenesis (DNL) 70. All of these processe are 
increased in subjects with insulin resistance and T2D 70. The resulting increase in 
VLDL secretion is mainly due to increased production of a subgroup of VLDL 
called VLDL1 71-72. These particles are larger and contain more triacylglycerols 
than the smaller VLDL2 particles. Furthermore, the VLDL1 particle also displays 
altered kinetic properties. For instance, increased secretion of VLDL1 leads to a 
reduction in the catabolic rate of apoB-containing lipoproteins, in particular LDL 
and IDL, resulting in an increased plasma concentration of these particles 73-75. 
The formation of sdLDL is closely linked to hypertriglyceridemia 76 and it has 
been shown that the VLDL1 level is a major predictor of LDL size in individuals 
with and without T2D 77-78. The mechanisms involved are thought to be related to 
the reduced clearance and prolonged residence time of apoB-containing 
lipoproteins in the circulation 79. This allows the exchange of triacylglycerols and 
cholesterol esters between VLDL and LDL, mediated by cholesterol ester transfer 
protein (CETP). In this process LDL becomes depleted in cholesterol esters and 
enriched in triacylglycerols, which makes it an excellent substrate for hepatic 
lipase. Hepatic lipase is commonly increased in patients with the metabolic 
syndrome and consequently, the prevailing condition favors the formation of 
sdLDL 80-82. A number of observations witness that the abundance of sdLDL is 
linked to an increased risk of CVD 83-86. The small particle size has been proposed 
to be the major reason for the increased atherogenicity, since this would favor 
penetration into the vessel wall 87. Furthermore, sdLDL particles have a higher 
affinity for proteoglycans than larger LDL 88-89 and also show increased 
susceptibility to oxidation 90-91.  
18
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HDL is considered beneficial and atheroprotective mainly due to its involvement 
in RCT. In a dyslipidemic state the increased triacylglycerol concentration and 
secretion of large VLDL1 particles will lead to a reduction in the amount of HDL 
particles 92-93. Again, CETP is involved, enriching the HDL particles with 
triacylglycerols. This enrichment has been shown to increase the clearance of 
HDL through an increased activity of hepatic lipases 94-95. In association with this 
metabolic alteration, the HDL particles progressively lose normal biological 
activities. Such altered HDL particles have been called “functionally defective” 96 
and show signs of reduced cholesterol efflux capacity 97-98 as well as reduced 
anti-oxidative 49, 99-100 and anti-inflammatory properties 101-102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The metabolic syndrome is associated with an intrahepatic lipid accumulation. This 
accumulation, which is the result of increased de novo lipogenesis (DNL) and increased 
utilization of the plasma fatty acid (FA) pool, results in increased production of large 
triglyceride-rich VLDL1. These particles have reduced clearance and the prolonged plasma 
residence time are associated with the formation of small dense LDL (sdLDL) and reduced 
levels of HDL, which are both proatherogenic events.     
  
Liver 
TAG
VLDL
2
VLDL
1
VLDL
+85%
IDL
+85%
LDL
Plasma
FA pool
FA
CM
remnants
TAG
Glucose
-37%
-54%
+45%
+45%
DNL
STORAGE
Adipose 
Tissue
sdLDL
HDL
19
BIOLOGICAL BACKGROUND 
20 
 
Dyslipidemia and liver fat 
Nonalcoholic fatty liver disease (NAFLD) is a disease characterized by increased 
hepatic triacylglycerol levels. It ranges in severity from simple fatty liver (hepatic 
steatosis), with benign prognosis, to a potentially progressive form, nonalcoholic 
steatohepatitis, which might lead to liver fibrosis and cirrhosis. The disease is 
associated with obesity, T2D, hypertension and hyperlipidemia 103-104, and has 
therefore been recognized as the hepatic component of the metabolic syndrome 
105. The mechanisms leading to excessive accumulation of triacylglycerols in the 
liver are mainly linked to an increased delivery of fatty acids from peripheral 
adipose tissue, and enhanced de novo lipogenesis (DNL) in the liver itself 106. By 
using a multiple-stable-isotope approach, Donnelly et al. estimated the 
contribution of DNL to hepatic triacylglycerol content in insulin resistant NAFLD 
subjects to be almost 30% 107. This can be compared to a DNL contribution of 5% 
under non-pathological conditions 108. This might be important in driving the 
dyslipidemia since a strong correlation exists between DNL and secretion of 
VLDL particles 106. This secretion, which is mainly the result of increased number 
of VLDL1 particles, is under normal conditions suppressed by the action of 
insulin. However, in subjects with fatty liver, this suppression is reduced 109. 
The connection between liver fat and insulin resistance is more uncertain. 
Emerging data suggests a causal role of intrahepatic lipid accumulation for the 
development of hepatic insulin resistance 110-112. Even though it has been shown 
in several rodent models that reducing the intrahepatic triacylglycerol depots 
will improve insulin sensitivity 113-115, this is most likely not a consequence of 
reduced triacylglycerol levels per se. Instead there is much evidence pointing to 
the importance of lipid intermediates such as diacylglycerols and ceramides in 
the development of insulin resistance 116-117.  
 
Dyslipidemia and apoCIII 
The plasma level of apoCIII is increased in patients with dyslipidemia and 
correlates well with the levels of triacylglycerols 118. Furthermore, in a number of 
studies with angiographic or clinical end points, plasma concentrations of 
apoCIII, or apoCIII-containing apoB particles, have been shown to be strong 
independent risk factors for cardiovascular disease 119-123. Genetic studies have 
also shown the importance of apoCIII levels for predicting cardiovascular 
disease. In a study published recently by Pollin and coworkers, it was shown that 
carriers of a heterozygous null mutation in the gene encoding for apoCIII had 
lower LDL and triacylglycerol levels as well as an increase in HDL levels. 
Furthermore, subclinical atherosclerosis was also lower in these subjects 
indicating a cardioprotective effect of this lifelong deficiency 124.  
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The mechanisms for the increased risk of cardiovascular disease in patients with 
high apoCIII levels can, to some extent, be explained by the inhibitory effect of 
apoCIII on LPL, the enzyme responsible for lipolysis and catabolism of 
triacylglycerol-rich lipoproteins in the circulation. Furthermore, recent 
publications also suggest that apoCIII inhibits hepatic uptake of VLDL and LDL 
overriding the opposite influence of apoE when both are present 125-126. Both of 
these mechanisms result in a decreased catabolic rate and prolonged plasma 
residence time for apoB-containing lipoproteins. It was also reported that apoCIII 
facilitates the conversion of LDL into sdLDL 125, another proatherogenic event. 
In addition to the mechanisms described above, convincing evidence now 
indicates that apoCIII is a multifunctional protein with effects beyond metabolic 
regulation. In a number of elegant articles from Kawakami and coworkers, 
apoCIII has been shown to be directly involved in inflammatory events in the 
vascular wall. For example, apoCIII, alone or bound to apoB-containing particles, 
was shown to increase the adhesion of circulating monocytes to vascular 
epithelial cells, which is an important event in the inflammatory aspect of 
atherosclerosis 127. The mechanisms behind this were: (i) activation of 
monocytes and (ii) activation of vascular endothelial cells by protein kinase C 
(PKC) β, which results in an increased expression of vascular cell adhesion 
molecule 1 (VCAM-1) 128. The activation of PKCβ was further shown to inhibit 
insulin-mediated activation of the endothelial nitric oxide synthase (eNOS) 
pathway, reducing the amount of the vasodilatory and atheroprotective nitric 
oxide. In conclusion, these findings suggest novel mechanisms for apoCIII in the 
pathogenesis of atherosclerosis and further link dyslipidemia to endothelial 
dysfunction 129.  
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The pathogenesis of atherosclerosis 
A primary initiating event in atherosclerosis is the subendothelial accumulation 
of apoB-containing lipoproteins in susceptible areas of the artery wall 130. Even 
though LDL is considered the lipoprotein that is most prone for penetration into 
the subendothelium, remnant particles originating from partial lipolysis of 
triacylglycerol-rich CM and VLDL might also be retained 131-132. The retention is 
mainly mediated through the interaction of the apoB-containing particles with 
the artery wall proteoglycans (PGs) 133-135. There are two factors that influence 
the retention of apoB-particles. The first one is the serum concentration. It can 
easily be appreciated that an increased amount of particles will increase the 
chance for penetration and subsequent retention. Accordingly, LDL levels have in 
several large clinical studies been recognized as one of the most important risk 
factors for cardiovascular disease 93, 136. The other is the propensity of the 
particle, once inside the endothelium, to become trapped. This might be due to 
either intrinsic properties of the particle such as size, charge, protein and lipid 
composition, or properties of the surrounding such as endothelial permeability 
or PG characteristics.  
Once trapped inside the intima, the lipoproteins are exposed to enzymatic and 
non-enzymatic modifications. Oxidation plays an important role due to the 
generation of oxidized phospholipids. These are known to be mediators of 
inflammatory cell recruitment and endothelial activation 137-138. Oxidation might 
be the result of enzymatic attack by myeloperoxidase and lipoxygenase, or by 
non-enzymatic attack by reactive oxygen species 139-140. Alternatively, secretory 
phospholipase A2 (sPLA2) might be responsible for producing lyso-
phosphatidylcholine, which is known to be a proinflammatory lipid involved in 
the atherogenic process 141-143. Another modification thought to be important is 
caused by secretory sphingomyelinase (SMase), which is responsible for 
mediating the conversion of sphingomyelin to ceramide. This increase in 
ceramide promotes lipoprotein aggregation, which facilitates its uptake by 
arterial wall macrophages, leading to foam cell formation 144. These mechanisms 
of lipoprotein modifications are accompanied by an inflammatory response and 
together they accentuated the essence of the complex pathogenesis of 
atherosclerosis.     
The progression of the disease results in an expansion of the atheroma and the 
development of the lipid core. It is thought that much of the non-cellular material 
located in the basal intima originates from the death of foam cells and smooth 
muscle cells. The core is also filled with lipid debris originating from dead cells as 
well as from free lipoproteins 145.  
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STUDY POPULATIONS 
Subjects from two major study cohorts have been used in the work included in 
this thesis. These studies are described shortly below 
 
Fenofibrate Intervention and Event Lowering in Diabetes  
In paper II the study subjects were recruited from the cohort originally included 
in the “Fenofibrate Intervention and Event Lowering in Diabetes” (FIELD) trial 
146. FIELD was a double-blind, placebo-controlled trial investigating the benefits 
of using fenofibrates for the prevention of coronary heart disease in people with 
T2D. The main eligibility criteria were: T2D with onset after 35, men and women 
between 50 and 75 years of age, average total cholesterol between 3.0-6.5 mM 
and triacylglycerol/HDL ratio > 4.0 or triacylglycerols > 1.0 mM. The trial, which 
was performed between 1998 and 2000, was performed in Australia, New 
Zeeland and Finland. In Finland Marja-Riitta Taskinen was one of the principal 
investigators. From the 9795 individuals that participated, 270 were recruited 
from the Helsinki Center. Of these, 101 volunteered for the study performed in 
paper II. The control group was recruited according to supplemental material in 
paper II. 
 
Diabetes in Women and Atherosclerosis 
In paper III the subjects were chosen from the community-based study “Diabetes 
in women and atherosclerosis” (DIWA). This was performed during 2001-2003, 
with Björn Fagerberg as principal investigator, and involved all the 64-year-old 
women living in Gothenburg, Sweden. Of the 4586 women invited, 2595 
participated and went through a screening examination, which included a 
glucose tolerance test. In addition, the examination also included anthropometric 
measurements together with a questionnaire regarding previous disease, current 
medication, smoking habits and heredity for diabetes. Subjects from this cohort 
were selected with the inclusion criteria stated in paper III. 
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LIPIDS 
Once considered passive bystanders, with the only functions as providers of 
energy and a basic structure of membranes, lipids are now considered 
multifunctional and it is difficult to find an area of cell biology where lipids do not 
play important roles as signaling or regulatory molecules. The importance of 
understanding lipid biology, for academic but also for clinical chemistry and 
pharmaceutical industry, is essential since alterations in lipid metabolism is 
involved in the pathogenesis of several common diseases such as T2D, 
Alzheimer’s disease, schizophrenia, cancer and atherosclerosis. 
  
Definition and classification 
Even though most lipid chemists and biochemists have a pretty clear picture of 
what is meant by the term lipid, there is no satisfactory and widely accepted 
definition of the term. In many textbooks, lipids are often described as naturally 
occurring substances that are hydrophobic in nature and soluble in organic 
solvents 147. Even though this is true in most cases, there are substances that we 
now see as lipids (saccharolipids for example) that are more soluble in water 
than in chloroform and, vice versa, several peptides and very hydrophobic 
proteins are actually soluble in chloroform 148. There are other definitions that 
use a more biological approach. William Christie defines lipids as “fatty acids and 
their derivates and substances related biosynthetically or functionally to these 
compounds” 149.  
In an effort to reach a consensus, several of the world leading lipid researchers 
recently proposed a lipid classification system 150. Here lipids are defines as 
“hydrophobic or amphipathic small molecules that may originate entirely or in 
part by carbanion-based condensation of thioesters or isoprene units”. They also 
make a classification of lipids into 8 groups based on chemical and structural 
similarities (table 2) and propose schemes for nomenclature. This effort, which is 
made with the intention of facilitating the systematization and cataloging of 
lipids, will be very useful when creating lipid databases for the use in lipidomics 
and system biology.  Below will follow a short description of the lipid classes 
relevant for the work included in this thesis.  
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Table 2. Lipid classification as suggested by Fahy et al. 150  
Lipid class Abbreviation Example 
Fatty acyls FA Fatty acid, eicosaniod 
Glycerolipids GL Triacylglycerol 
Glycerophospholipids GP Phosphatidylcholine 
Sphingolipids SP Ceramide, Sphingomyelin 
Sterol lipids ST Cholesterol, Cholesterol ester 
Prenol lipids PR Retinol 
Saccharolipids SL Lipid X 
Polyketides PK Tetracycline 
 
Structure and function 
Fatty acyls 
 
(Arachidonic acid) 
This group includes the fatty acids, which are synthesized in a fashion that leads 
to ethylene (C2H4)-spaced products of different chain lengths. Double bonds are 
included at various positions and at various stages in the biosynthetic and 
metabolic processes resulting in a vast amount of different molecules. Besides 
being used as building blocks for several other lipid classes, the fatty acids, and 
especially arachidonic acid, are also important precursors for biologically active 
lipids such as prostaglandins, leukotriens and thromboxanes.  
 
Glycerolipids 
 
 
(Triacylglycerols) 
 
The glycerolipids include all the lipids that contain a glycerol backbone, except 
for the glycerophospholipids, which constitutes a separate category.  The 
glycerolipids are dominated by the mono-, di-, and triacylglycerols, which all 
OH
O
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have fatty acids esterified to the glycerol backbone. Triacylglycerols are the main 
source of energy in the body while the diacylglycerols functions as membrane 
constituents but also, under certain conditions, as intracellular messengers 151. 
Increased intra-cellular levels of diacylglycerols have also been suggested to be 
induce insulin resistance 152.    
 
Glycerophospholipids 
 
 Choline 
 (Phosphatidylcholine) 
 
 
 Ethanolamine 
 (Phosphatidylethanolamine) 
 
 
 
 Serine 
 (Phosphatidylserine) 
 
 
 
 Glycerol 
 (Phosphatidylglycerol) 
 
 
 
 Inositol 
 (Phosphatidylinositol) 
 
 
Even though containing a glycerol backbone, the glycerophospholipids are 
considered as a separate group because of their high abundance and importance 
as membrane constituents. The glycerophospholipids are ubiquitous in nature 
and can be subdivided into distinct classes depending on the polar head group 
attached to the sn-3 position on the glycerol backbone. The phosphatidylcholines 
and phosphatidylethanolamines are the most common sub-classes and may 
constitute as much as 55 and 35 %, respectively, of the total lipids in certain 
tissues 149. Other sub-classes include phosphatidylserine, phosphatidylglycerol 
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and phosphatidylinositol. Hydrolysis of phospholipids can occur by the action of 
phospholipases, which will lead to the production of lyso-phospholipids and free 
fatty acids. Both lyso-phosphatidylcholine and lyso-phosphatidic acid are potent 
signaling molecules and have been implicated in several disease states 153. 
Furthermore, in response to various cell stimuli, the action of phospholipase C on 
phosphatidylinositol 4,5-bisphosphate leads to the production of diacylglycerol 
and inositol 1,4,5-triphosphate, which are both secondary messengers in what 
can now be considered to be a classical pathway 154-155. 
 
Sphingolipids 
 
(Ceramide) 
 
The sphingolipids are a complex family of compounds that share a sphingoid 
base backbone as a common structural feature. The sphingoid base is 
synthesized from a serine and a long-chain fatty acyl-CoA and further 
metabolism leads to the generation of several other sub-groups including 
ceramides, sphingomyelins, and glycosphingolipids (such as glucosylceramides 
and gangliosides). Ceramides, which are an important sub-group, have a fatty 
acid of varying length (mostly between 16-26 carbons long) attached to the 
sphingoid base backbone. They are bioactive molecules that have been 
implicated in a variety of physiological functions including apoptosis, cell growth 
arrest, differentiation, cell senescence, cell migration and adhesion 156. They are 
also being considered as regulators of insulin signaling and action 157.  
 
Sterol lipids 
 
 
(Cholesteryl ester) 
 
The sterols are widely studied in mammalian systems. Cholesterol is an 
important constituent of biological membranes and also the precursor for many 
steroids (hormones) such as estrogen, testosterone and cortisol. The storage 
NH
O
OH
CH2OH
O
O
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form of cholesterol, the cholesteryl ester, is highly abundant in many cells and 
also in the circulation as a major part of the lipoprotein particles.  
 
Lipid diversity 
Analysis of mammalian tissue suggest that the number normally-abundant fatty 
acids is typically in the order of 30-60 158. By combining these with different lipid 
backbones and head groups, a large number of different molecular lipids can be 
formed. For example, the theoretical number of triacylglycerols that could be 
generated from 50 fatty acids would be more then 100 000. Furthermore, more 
than 300 different oligosaccharide side chains and 60 different sphingoid bases 
have been characterized so far in the sphingolipid class 159. By combining these 
with 50 fatty acids the number of theoretical combinations reaches almost 1 
million. Fortunately, from an analytical point of view, many of these doesn’t exist, 
or exist at very low abundance, due to non-random distribution of fatty acids and 
head groups. For example, phospholipids often have saturated fatty acids at sn-1 
position while the sn-2 position is occupied by an unsaturated fatty acid 158. 
Another example is ceramides, which usually consists of long saturated fatty 
acids and sphingosine as the sphingoid base 160. Nonetheless, the number of 
molecular lipids is huge and therefore a comprehensive investigation of the 
lipidome relies on powerful analytical techniques, such as mass spectrometry 
(MS). 
 
Lipid abbreviations 
Throughout this thesis, and also in the articles included, molecular lipids are 
denoted with the abbreviation of the lipid class followed by the number of 
carbons and double bonds included in the fatty acids attached to the core 
structure. For example, PC 16:0/18:1 means phosphatidylcholine with a fatty 
acid comprising  of 16 carbons with no double bonds (palmitic acid) on the sn-1 
position, and a fatty acid comprising 18 carbons with 1 double bond on the sn-2 
position on the glycerol backbone. If the positions of the fatty acids are unknown 
it is annotated PC 16:0-18:1. Furthermore, the fatty acid denoted 18:1 in the 
example above might be either oleic or vaccenic acid depending on the position 
of the double bond. If it was oleic acid the structure would be written PC 
16:0/18:1 n-9 with the “n-9” informing us that the double bond is positioned 
between carbon number 9 and 10 counting from the methyl end. (These are 
sometimes called omega-9 fatty acids). If the fatty acid was vaccenic acid, the 
lipid would have been written PC 16:0/18:1 n-7. 
28
LIPIDOMICS PLATFORM 
29 
 
LIPIDOMICS PLATFORM 
“…through chemistry one could understand the nature of evils in the shape of 
disease, and the means of curing or mitigating them”.  
J. L. W. Thudichum 1876 
 
Lipidomics 
Since the term genomics was introduced in the middle of the 80’s (supposedly by 
the scientist Thomas Roderick 161) a number of different -omics have now 
emerged in the field of biology. One of them is metabolomics, which has the 
ambitious task of characterizing all the metabolites of a biological system (such 
as a cell or organism) at a given time and under certain conditions. Metabolomics 
lies further down in the -omics cascade and, in some aspects, therefore more 
accurately reflects the physiological state of the cell, tissue or organism of 
interest. This makes metabolomics a highly interesting alternative when 
searching for new diagnostic biomarkers or for evaluating therapeutic 
interventions. Furthermore, by combining data from metabolomics-, proteomics-, 
and genomics studies, inter-related information is attained that can be used to 
understand and predict the behavior of a system as a whole. This discipline is 
sometimes called systems biology.  
Lipidomics is categorized as a subgroup of metabolomics, and has been defined 
as “the system-level analysis and characterization of lipids and their interacting 
moieties” 158. Other definitions imply that lipidomics is more than just the 
characterization of lipids and involves also the comprehensive understanding of 
the influence of all lipids on a biological system 162. The emergence of this new 
discipline, which was first mentioned in a peer-reviewed scientific paper in 2003 
163, is built on the foundation of three major inter-related factors. First, the 
importance of lipids as a part of the etiology of diseases such as T2D, 
atherosclerosis, obesity and Alzheimer’s disease has been recognized. Secondly, 
researchers have realized that the metabolism of several molecular lipids and 
lipid classes are interwoven. Therefore, the study of specific pathways requires 
the analysis of multiple lipids. Finally, and perhaps most importantly, the field 
has expanded because of important developments in the arsenal of analytical 
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tools available. Of major importance is MS, which allows even low abundant 
lipids to be analyzed in a high-throughput manner.  
The analysis of lipids usually consists of three major parts: (i) lipid extraction, (ii) 
sample analysis (often by HPLC and MS), and (iii) data analysis and 
interpretation. These parts will be discussed below. 
 
Lipid extraction 
The first step in the analysis of lipids (unless imaging techniques are employed) 
is the extraction of the lipids and removal of non-lipid components from the 
tissue or biofluid of interest. This is in most cases achieved by extraction with 
organic solvents. A number of different organic solvents can be used, and the 
extractions can be tailored for high recoveries of specific lipid classes 149. Two of 
the most common methods for isolating a broad spectrum of lipid classes are the 
methods described by Folch, Lees and Sloane 164, and by Bligh and Dyer 165. The 
basic principle of these methods is that initially chloroform and methanol are 
added to the sample creating a mono-phase system that extracts the lipids from 
the sample matrix. Then an aqueous buffer is added, which cleans the lipid 
extract from non-lipid components.  
In the work included in this thesis, all extractions were made according to Folch 
et al. and the procedure has been automated by the use of a robot 166. The robot 
uses the 96-well format and the extraction, which is completed in about one 
hour, is performed in 1.3 ml glass inserts placed in a custom-made alumina block. 
Validation of the method revealed similar extraction recoveries and 
quantification accuracy compared to a manually performed extraction. In 
addition, the method resulted in increased reproducibility.  
Even though the Folch procedure is highly used and excellent for extracting lipids 
within a wide range of polarity, the routine and automated use of this method 
suffers from certain drawbacks, all related to the use of chloroform. Despite 
being an excellent solvent for lipids, chloroform is a known carcinogen with 
several negative effects on the environment and human health 167. Furthermore, 
the low solubility of water in chloroform reduces the sample to solvent ratio used 
in the initial mono-phase system of the Folch procedure to 1:20. This means that 
when using 1.3 ml glass vials only 30 μl of sample can be extracted. Despite the 
increased sensitivity of modern mass spectrometers, there still are occations 
when the analysis of low abundant lipids in certain matrices (such as 
cerebrospinal fluid or isolated cellular compartments) would benefit from using 
a higher initial volume of sample matrix. Finally, chloroform is a dense liquid 
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ending up at the bottom at the tube when adding the aqueous buffer to the 
extraction mixture. This means that the buffer and inter-phase have to be 
penetrated for recovery of the lipid-containing fraction. For some samples the 
water phase, and especially the inter-phase, can be filled with precipitate from 
proteins and other matrix components, which might disturb accurate recovery of 
a pure lipid fraction. Alternatives to the Folch procedure are therefore required. 
The Dole procedure is based on a ternary system of isopropanol, hexane and 16 
mM H2SO4 168. This system has an initial sample to solvent ratio of 1:5 and the 
lipids end up in the upper organic phase. However, this method is only suitable 
for non-polar lipids and show low recoveries for more polar lipids such as 
phospholipids and sphingolipids. Recently a method was described using methyl-
tert-butyl ether (MTBE), methanol and water (10/3/2.9; v/v/v) for the use in 
automated lipidomics applications 169. Although this method displays high 
recoveries for a broad range of lipids, it still suffers from low sample to solvent 
ratio in the first mono-phase system. An alternative method (manuscript in 
preparation) has been developed that is based on butanol, methanol, ethyl 
acetate, heptane and 1mM acetic acid. This method has a high sample to solvent 
ratio (1:4) and has an upper organic phase, which makes it ideal for automation.  
 
Chromatography of lipids 
Basics 
Chromatographic methods allow the separation of closely related analytes of 
complex mixtures. In all chromatographic methods the analytes are transported 
in a mobile phase that can be a gas, liquid or supercritical fluid. The mobile phase 
is forced through a stationary phase that is fixed inside a column or on a plate. 
Due to the differences in distribution of the analytes between the two phases, 
they will be separated from each other. The analytes that favors the mobile phase 
will travel rapidly through the stationary phase. In contrast, the analytes that are 
highly retained by the stationary phase will move slowly with the flow of the 
mobile phase.  
In gas chromatography (GC) the sample is vaporized and injected into a 
chromatographic column. The analytes are carried by a gas and allowed to 
interact with the stationary phase, which is normally a liquid (gas-liquid 
chromatography). A limitation of GC is the requirement of the analytes to be 
easily vaporized. This often requires time-consuming derivatization procedures 
to reduce the boiling point of the analytes. Another limitation of the GC 
methodology is the inability to analyze thermally unstable compounds. In the 
field of lipid analysis GC has been used extensively and even though it has been 
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replaced by HPLC in many applications, it is still the preferred technique for 
analyzing free fatty acids.  
The use of high-performance liquid chromatography (HPLC) (or high-
pressure liquid chromatography as it was originally called) has accelerated and is 
now the most widely used analytical separation method. One important reason 
for this is the applicability to substances of major interest for industry, many 
fields of science and the public. In HPLC, the stationary phase is contained inside 
a column with the dimensions normally ranging from 50-250 mm in length and 
1-5 mm in diameter. The stationary phase often consists of small beads (3-5μm) 
coated with different material depending on the separation required or, in other 
words, on the analytes of interest. In early work, HPLC was based on highly polar 
stationary phases such as water or triethyleneglycol supported on silica or 
alumina particles. Non-polar mobile phases, such as hexane and ethers, were 
commonly used. For historical reason, this type of chromatography is referred to 
as normal-phase and is today used for separations of analytes with relatively 
hydrophobic properties such as lipids. Even though normal-phase HPLC is used 
in several applications, more common today is reversed-phase HPLC. Here the 
stationary phase is nonpolar alkyl chains (e.g. C18 or C8) covalently bound to the 
support surface while the mobile phase is based on more polar solvents such as 
water, methanol and acetonitrile. The name reversed-phase originates from the 
fact that in this kind of HPLC, the elution order of the analytes is reversed 
compared to normal-phase. In normal-phase HPLC the least polar analyte is 
eluted first, while in reversed-phase it is eluted last. Besides the C18 and C8 
stationary phases mentioned above, several other exist such as cyano- and 
phenyl-bonded phases that give the column slightly different retention 
properties that might be useful for specific applications. Due to the robustness 
and applicability of reversed-phase HPLC it can be found in a number of different 
fields. Even though the method is usually used for more polar substances, it is 
also used extensively in the field of lipid analysis. 
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High-performance liquid chromatography of lipids 
The use of HPLC for the separation of complex lipid mixtures has been described 
extensively in the literature. Due to the wide range of polarity and 
hydrophobicity between different lipid classes, the columns and mobile phases 
used also varies depending on the application. Both normal- and reversed-phase 
methods have been employed with some only focusing on specific lipid classes, 
while others use a more general approach in an attempt to separate lipids with a 
broader array of polarity. In the work included in this thesis lipid classes have 
been separated on a silica column using normal-phase HPLC according to a 
method published by Homan et al. 170, which is based on a prior method 
originally published by Christie et al 171. Figure 6 shows a chromatogram 
generated from the separation of a mixture of lipid standards, using this method. 
In the work included in this thesis the HPLC method has been used for 
quantification of major lipid classes, but also as a lipid class purification system. 
By splitting the flow of the mobile phase post-column, selected lipids could be 
collected and further characterized using MS. The benefits of using this strategy, 
which has also been used by others 172-173, are mainly that the collected lipid class 
can be analyzed at lower concentrations (the sensitivity increased by a factor 3-8 
depending on the lipid class) in absence of a complex sample matrix that would 
otherwise suppress the signal and contaminate the ion source. Another 
advantage is that molecular lipids originating from other lipid classes, with the 
same (isobaric) or very similar mass, are removed, thereby facilitating 
identification and quantification. 
 
 
 
 
 
 
 
 
 
Figure 6. Chromatogram showing the separation of both non-polar and polar lipids using the 
method according to Homan et al. 170  
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Even though the retention of lipids in a normal-phase HPLC system is based on 
their polar moieties, the hydrophobic parts (such as fatty acids) will also have an 
effect on their retention time. Thus, the composition of molecular species in the 
beginning of an eluting peak will be slightly different then the later part. 
Therefore, precautions have to taken when using HPLC for the isolation of 
specific lipid classes that the chromatographic system is in equilibrium and that 
the collection is made with sufficient margins both before and after the eluting 
peak. Otherwise there is a risk of generating false lipid profiles 174. Figure 7 
shows no difference in the CE profile of isolated VLDL (from the DIWA subjects in 
paper III) analyzed from a total lipid extract or after pre-fractionation using 
HPLC. Similar comparisons have been made for other lipid classes to ensure the 
conservation of the lipid profiles after pre-fraction.  
 
 
 
 
 
 
 
Figure 7. No significant differences could be observed in the profiles of VLDL cholesteryl 
esters analyzed directly as a total lipid extract (black) or after pre-fractionation using HPLC 
(white).  
 
 
Mass spectrometry of lipids 
That MS was going to play an important role in lipid research was appreciated 
already 50 years ago. In a review article from 1960 the local pioneers in lipid MS 
Ragnar Ryhage and Einar Stenhagen stated that “…its wide applicability and 
power are not as yet fully appreciated” 175. In the following decades lipid MS, and 
especially GC/MS, would come to play a more important role within the field. 
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Since lipids are mostly nonvolatile compounds, much effort was made in the 
early days to get the lipids into gas-phase to be able to analyze them with GC/MS. 
With the advent of newer ionization techniques, especially electrospray 
ionization, the situation has now profoundly changed so that it is now possible to 
directly, without any tedious derivatization steps, produce gas-phase molecular 
ions for most lipids. As a consequence, GC has in many applications been 
replaced with HPLC or direct infusion techniques.  
 
Basics 
MS is a powerful analytical tool that can supply both qualitative and quantitative 
data. It has the capability to provide information about the molecular weight, 
elemental composition and also structural composition, which can be valuable 
when analyzing unknown analytes. For known analytes, it is mainly used as a 
selective mass filter, which means that it can sort out the mass of the analyte 
from interfering substances and therefore provide extremely selective data. The 
mass spectrometer consists of three major parts: the ion source, the mass 
analyzer and the detector. These will be described below.  
 
Ion sources 
Since the mass spectrometer utilizes external electric and magnetic fields to 
move and manipulate the analytes, one requirement is that the analytes become 
ionized before entering the mass analyzer. The second requirement is that the 
ions are in gas phase. Both of these are taken care of in the ion source. There are 
a number of different ion sources available and the choice depends heavily on the 
application. Here only the most commonly used ion source for coupling HPLC to 
MS will be mentioned, electrospray ionization (ESI). The development of ESI 
for mass spectrometric applications started in the middle of the eighties in the 
lab of John Fenn 176, who was later rewarded with the Nobel Prize in 2002.  When 
using ESI in combination with HPLC, the HPLC effluent is emitted through a small 
capillary that is subjected to high voltage (1-3 kV). This voltage enables the fluid 
to form a Taylor cone, which is enriched with ions at the tip. From this tip a spray 
of charged droplets is ejected towards the mass analyzer (figure 8). The size of 
the droplets is decreased as a result of evaporation, which is assisted by the hot 
flow of nitrogen gas that is passed through the front of the ion source. In a 
process that has still not been fully elucidated 177 ions are subsequently formed 
from these charged droplets and enter the inner parts of the mass spectrometer.  
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Figure 8. Electrospray ionization interface. 
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analysis. If the analyte is of low abundance, which often is the case for bioactive 
lipids, then the sensitivity will be an issue. Even though the detector is 
responsible for signal output, the mass analyzer contributes to the sensitivity of 
the instrument by modulating the signal/noise ratio. Quadrupole and TOF mass 
analyzer are described in more detail below.  
A quadrupole consists of four circular (or ideally hyperbolic) parallel rods. 
Opposite rods are electrically connected and applied with a combination of 
direct-current (DC) and a radiofrequency (RF) potential. The ions will travel 
axially through the center of the four rods where they will be affected by 
electrical forces. The force will depend on the combination of the DC and RF 
potential. This means that for a certain m/z only a specific combination of these 
potentials will enable the ion to maintain a stable trajectory through the 
quadrupole and reach the detector. Other ions with different m/z will be bent in 
either the x or y-axis and will be lost. In a quadrupole a spectrum is generated by 
stepwise scanning through the m/z range of interest while recording the amount 
of ions reaching the detector. 
In a time-of-flight (TOF) mass analyzer the ions are accelerated by a potential 
often perpendicular to the ion path generated in the ion source, so called 
orthogonal acceleration (figure 10). Since this will give the same kinetic energy 
to all ions (ideally), the difference in mass between different ions will give them 
different velocities. The ions are then allowed to drift in a field-free vacuum 
region towards the detector. The difference in time between the acceleration and 
the pulse generated from when the ions hit the detector is the time-of-flight. This 
can be expressed as:    
???? ?
?
?
? ??
?
???
?? ??
?
?
 
Where L is the distance travelled, v is the velocity of the ion after the acceleration, 
m is the mass of the ion, q is the charge and V is the acceleration potential.  
 
Detectors 
After passing the mass analyzer, the ion beam is detected and transformed into a 
usable signal by the detector. Several types of detectors currently exist and they 
vary according to the design of the mass spectrometer and the application 
requirements. For all of them however, characteristics such as high sensitivity 
and linearity are highly desired. At present, the most commonly utilized detector 
is the electron multiplier (EM). This detector comes in a number of different 
variants but all work by the same principle. Ions exiting the mass analyzer strike 
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a conversion dynode. This creates secondary ions that generate an electron 
cascade multiplying the single incident with a factor of 106 or more. A 
multichannel plate (MCP) is an example of an EM detector that is frequently 
found in TOF instruments. The design of this detector allows very rapid readout 
and response, which is required when using a TOF mass analyzer. The drawback, 
at least so far, is that the MCP has a tendency to get saturated at high ion 
abundances, which in turn gives nonlinearities for count rates above a few 
thousand incident particles per second.  
 
Tandem mass spectrometry 
A big step in the analytical capability of MS was the introduction of collision 
induced dissociation or decomposition (CID) 178. CID of preselected precursor 
ions often occurs in a separate part of the mass spectrometer, called the collision 
cell, and generates a characteristic and often unique precursor-dependant 
fragment pattern. By using two mass analyzers in series (tandem), separated by a 
collision cell, new methods could be employed (figure 9). Below different 
methods of performing tandem mass spectrometry (MS/MS) is illustrated with 
the triple quadrupole (QqQ). In this mass spectrometer, both mass analyzers are 
quadrupoles. However, MS/MS can also be performed in instruments with a 
different set-up.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mass spectrometric methods that are based on the collision induced dissociation
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One way of performing MS/MS is to filter out the precursor ion of interest in the 
first quadrupole and expose it to CID in the collision cell. The generated 
fragments are then measured in the second quadrupole. This method is called 
product ion scanning and the fragmentation pattern can be used for structure 
elucidation of unknown compounds.  
Precursor ion scanning (PIS) and neutral loss (NL) scanning are both powerful 
tools when working with lipids since they take advantage of the structural 
similarities of the molecular lipids within a certain lipid class. In PIS using a QqQ, 
all molecular ions (or molecular ion adducts) in a certain predefined mass range 
are exposed to CID and in the second mass analyzer the characteristic fragment 
ion(s) is/are monitored. In the cases where CID generates a neutral characteristic 
fragment, the two mass analyzers are scanned at a constant mass difference 
corresponding to the mass of the lost, neutral fragment. This is called neutral loss 
scanning.  
An often used method for quantification is selected (or single) reaction 
monitoring (SRM). This is preferably used in combination with HPLC and takes 
advantage of the specific fragmentation pattern of an analyte of interest. By fixing 
both the first and the second mass analyzer on masses that are highly specific for 
the analyte, a very selective, and thus sensitive, method can be created for 
quantification. If several compounds are monitored simultaneously, the method 
is called multiple reaction monitoring (MRM).  
 
Quadrupole time-of-flight mass spectrometry 
Hybrid mass spectrometers combining both the quadrupole and time-of-flight 
technologies emerged in the mid 90s 179. As shown in figure 10, the QqTOF mass 
spectrometer contains a resolving quadrupole (Q1), a collision cell, and an 
orthogonally angled TOF analyzer. Normally QqTOF instruments are more 
sensitive than triple quadrupoles working in scanning mode because it has the 
benefit of being able to record all ions simultaneously in the TOF analyzer. But 
when working with MS/MS methods such as PIS or MRM, the sensitivity of the 
triple quadrupole is usually superior. This is mainly due to the low duty cycle (5-
30%) of the TOF mass analyzer. A duty cycle can in this case be defined as the 
proportion of the ions entering the accelerator area that are actually accelerated 
towards the detector. However, this limitation was overcome when bunching and 
trapping technologies were developed 180. By temporarily trapping fragment ions 
within a certain mass range in the collision cell before releasing them into the 
TOF analyzer, the duty cycle could reach close to a 100% for ions in the low mass 
range 180. This has increased the sensitivity of the QqTOF instruments, which are 
now in the same order of magnitude as the triple quadrupoles. Other important 
features of the QqTOF are the inherited characteristics of high resolution and 
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1 x 10-6 Torr
Sample ions
mass accuracy. This allows the detection of ions within a small mass range 
(typically 0.1 Da), which minimizes the chance of detecting a false positive and 
biased quantification. Furthermore the TOF analyzer allows the simultaneous 
recording of a theoretically unlimited number of ions. This makes it an attractive 
alternative for performing multiple PIS.  
Most mass spectrometric analyses performed in the work included in this thesis 
utilizes this type of instrument, and are based on methods developed by Ekroos 
and Ejsing 181-183.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Overview of the QqTOF mass spectrometer.  
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Nano-ESI interface  
For ordinary ESI sources the flow rates used for introducing the sample into the 
mass spectrometer are in the μl/min range. Efforts to reduce these flow rates 
have in recent years resulted in the development of several types of nano-ESI 
sources (nl/min range). Ideally, these ion sources benefit from increased 
sensitivity, primarily as a result of reduced droplet size in the ionization process. 
Reduced droplet size leads to an increased surface/volume ratio, which makes a 
large portion of the analytes available for desorption and subsequent ionization 
184. Another benefit of using nano-ESI is a reduced ion suppression, which can 
seriously hinder ordinary ESI 185. Despite these advantages, the nano-ESI sources 
have not yet enjoyed the same success as their higher flow rate analogues 186, at 
least in the field of lipidomics. One reason for this is the lack of robustness of 
these sources, which are highly dependent on the quality and nature of the spray 
emitter for producing a stable spray. Other problems are that methods have been 
difficult to automate and often suffer from cross-contamination. 
For the work included in this thesis, a static, chip-based nano-ESI interface 
(Nanomate; Advion BioSciences, Ithaca, NY), has been employed. This system, 
which is compatible with the 96-well system, uses conducing tips to aspirate the 
sample. The tip is then turned 90 degrees and docked with a 5μm nozzle in an ESI 
chip, positioned directly in front of the orifice of the mass spectrometer. With the 
aid of a gas pressure and high voltage, a fine spray is formed on the back of the 
chip. Using this interface, 5μl of sample can be infused during 30 minutes with a 
flow rate of approximately 150 nl/min. The low flow rate reduces ion suppression 
and increases the sensitivity of the analysis.  
 
Approaches used for lipid characterization 
As a consequence of the great diversity in structure, physicochemical properties, 
and relative abundance of different lipids, a number of methods and approaches 
for performing lipid-based MS are currently available. Furthermore, the field is 
expanding rapidly and several attempts have been made to create schemes for 
classification of the different approaches. However, this can often be confusing 
since a similar approach can be named differently by different research groups. 
Below, and in figure 11, I have outlined what I see as the most common 
approaches. In the following sections I will discuss their strengths, differences 
and usefulness for the analysis of different lipid classes.  
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Global vs. targeted lipidomics 
Depending on the hypothesis and information known beforehand, the lipidomics 
approach can be either global (non-targeted), or targeted. This means that if 
there is much information known and the hypothesis addresses a specific aspect 
of the lipidome, a more precise and specific approach can be used. On the other 
hand, if not much is known in the context of expected lipidome, it may be 
reasonable to apply a global approach. Global lipidomics means unselectively 
mapping of the entire spectrum of lipids, including all molecular species, in a 
biological system 187. This often starts with a Folch extraction to recover lipids 
with a wide range of polarity. Then analysis of the total lipid extract is made 
using HPLC (or UPLC) in combination with high accuracy mass spectrometers, 
such as TOF, Orbitrap or FTICR instruments 188-190. The possible advantage of 
using this approach is that it allows the detection of previously unknown or 
poorly characterized lipids. These can then be identified in a complementary 
analysis, using a more targeted approach. The global approach generates 
substantial amounts of data and much effort has to be made in terms of data 
processing, such as peak detection, peak alignment and normalization. However, 
absolute quantification is a challenge due to the complexity of the analysis and 
lack of adequate standards.  
In contrast, a targeted approach focuses on specific lipids or lipids classes. This 
means that selective MS methods, such as precursor ion and neutral loss 
scanning, can be used, which increases the sensitivity of the analysis. Using this 
definition, a targeted approach means everything from a simple SRM method 
quantifying shingosine-1-phosphate to profiling of several hundreds of 
triacylglycerols using neutral loss scanning. Using this approach, which is more 
common than a global approach, quantitative data for hundreds or lipids can be 
attained with high accuracy and precision. A targeted approach can be based on 
either HPLC/MS or shotgun methods, which are discussed below. In the work 
included in this thesis, all analyses are made with a targeted approach. 
 
Shotgun- vs. HPLC-based lipidomics 
While HPLC/MS-based methods uses chromatographic separation in 
combination with the MS analysis (on-line), shotgun techniques infuses the lipid 
mixture directly. The term shotgun lipidomics was coined by Han and Gross and 
first appeared in a peer-review paper in 2005 191. Since then several articles have 
been published describing important innovations in this type of lipidomics such 
as intrasource separation of lipids 192-196. The strategy behind intrasource 
separation of lipids is to create an environment in the ion source that results in 
maximal ionization of the lipids of interest, while reducing this ionization of 
other lipids. Examples of parameters that can be adjusted, in order to attain 
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Figure 11. Workflow showing different strategies that can be used for performing 
lipidomics.  
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using off-line HPLC prior to mass spectrometric analysis. Diacylglycerols and 
triacylglycerols were quantified using shotgun analysis while the ceramides were 
quantified using HPLC/MS/MS. Cholesteryl esters, free cholesterol, 
phosphatidylcholines, sphingomyelins and lyso-phosphatidylcholines were 
analyzed directly from the total lipid extract using a shotgun approach.  
Imaging 
During a traditional lipid analysis of tissue, no information is obtained about lipid 
localization. For this purpose, powerful techniques are now emerging capable of 
generating a two dimensional (and also three-dimensional) picture of the lipid 
distribution in both animal and plant tissue. The techniques most commonly 
used are matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
MS 201 and time-of-flight secondary ion MS (TOF-SIMS) 202.  
 
Ion suppression 
Due to the complexity and relatively high concentration of lipids in the sample 
mixture the shotgun approach will be associated with some degree of ion 
suppression (charge competition in the ion source). For the critics of the shotgun 
approach, this is the major argument since it is suggested to hamper accurate 
quantification 203. However, using the shotgun approach, the ion suppression is 
expected to be more constant during the analysis of each sample and 
furthermore, the ion suppression is lipid class dependant. This means that these 
effects will be corrected for by the use of one, or several, lipid class specific 
internal standards, which should be endogenously non-existing 166.  For a 
HPLC/MS-based analysis on the other hand, the ion suppression will vary during 
the chromatographic run due to the difference in the eluting mobile phase 
composition (for gradient HPLC/MS methods) and sample matrix. In other 
words, the signal intensity of different molecular lipids from the same lipid class 
will not only depend on the inherent physicochemical properties of the molecule, 
but also on the retention time. To ensure correct quantification, isotopically 
labeled internal standards have to be used for each molecular lipid, which in 
many applications is unrealistic. To conclude, both of these approaches suffer 
from ion suppression and, even though more substantial, ion suppression during 
shotgun lipidomics might be easier to control. 
 
Methods used for lipid class profiling 
In the papers included in this thesis the profiling of lipid classes (except for 
ceramides) have been performed using a shotgun approach on a hybrid QqTOF 
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instrument as described above. Furthermore, all analyses performed on the 
QqTOF instrument have utilized (multiple-) PIS. A short description of the settings 
and conditions used for the different lipid classes is presented below and in table 
3.  
The non-polar nature of cholesteryl esters make them hard to ionize using the 
ESI interface. However, in the presence of ammonium acetate (5 mM) they will 
form [M+NH4]+ adducts, which will generate a protonated cholestadiene fragment  
when exposed to CID 204-205. This fragment was used for PIS according to earlier 
publications 205. The deuterated cholesteryl-d6-octadecanoate was used as internal 
standard. The high abundance of cholesteryl esters in both the VLDL and LDL 
fraction made it possible for analysis by the shotgun approach.     
Ionization of triacylglycerols are also dependant on adduct formation. 
Ammonium or sodium adducts are common 206-208 but also lithium adducts have 
been employed successfully for the characterization of triacylglycerol isomers 209-
210. Due to the huge number of unique species that can be formed from common, 
naturally-occurring fatty acids, the complete characterization of triacylglycerols 
using MS is a challenge. Strategies used include both UPLC/MS methods 211-212] and 
shotgun methods 197, 207, 209-210. In the work presented in this thesis, triacylglycerols 
were characterized using multiple PIS by selecting 40 of the most common 
diacylglycerol fragments generated during CID. While direct analysis of VLDL 
triacylglycerols was feasible, triacylglycerols from LDL first required purification 
by HPLC.  
Two articles have been published recently dealing with the shotgun analysis of 
diacylglycerols 198, 213. Due to the low abundance of this lipid class, a purification 
step is necessary to reach the sensitivity required. In the work included in this 
thesis, diacylglycerols were purified using off-line HPLC. Similar to the 
triacylglycerols, specific fragments formed due to the loss of a fatty acid, are 
generated during CID of ammoniated diacylglycerols. These monoacyl fragments 
were used for PIS. For triacylglycerols and diacylglycerols, internal standards 
containing heptadecanoic (C17:0) fatty acids are used.  
Lipoproteins have a very high relative abundance of phosphatidylcholine, which 
together with sphingomyelin constitutes the major part of the monolayer 
surrounding the hydrophobic core of the lipoproteins. Both of these lipid classes 
are easily ionized in positive mode, primarily due to their quaternary nitrogen 
situated in the choline headgroup 182, 214-215. Upon CID, both phosphatidylcholine 
(and also lyso-phosphatidylcholine) and sphingomyelin generates a fragment 
due to the loss of the choline head group. Therefore these three lipid classes were 
profiled together in positive mode using PIS of m/z 184.1. 
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When performing PIS of phosphatidylcholines in positive mode, only the brutto 
composition is attained. This gives only limited information about the fatty acid 
composition. For example, the two isobaric phosphatidylcholine species PC 
16:0/18:1 and PC 16:1/18:0 both give rise to a peak at m/z 760.5 using PIS in 
positive mode. Additional information of phosphatidylcholine lipid species was 
therefore attained using multiple PIS in negative mode 181-183. In negative mode 
phosphatidylcholines are readably detected as acetate adducts. When exposed to 
CID these adduct ions generate several fragments, including individual fatty acid 
carboxylate ions. By taking advantage of the strengths of the QqTOF instrument, 
about 30 different fatty acid fragments were monitored simultaneously, allowing 
the identification of molecular lipids.   
Due to the low abundance of ceramides in lipoprotein fractions they were not 
measured by shotgun analysis. Instead a HPLC/MS/MS method was employed. 
During CID of sphingosine-based ceramides, a characteristic fragment at m/z 264 
is generated 216. Using this product ion, an MRM method was developed for the 
quantification of the most common ceramides 
  
 
Table 3. Summary of the analytical methods employed for the work included in my 
thesis 
Lipid class Analysis Reference 
Cholesteryl esters +PIS m/z 369.3 204-205 
Triacylglycerols +MPIS a 166 
Diacylglycerols +MPIS b 166 
Ceramides + MRM m/z 264.3 216 
Phosphatidylcholines 
+PIS m/z 184.1       
-MPIS c 
181-183 
Sphingomyelins +PIS m/z 184.1 182 
Lyso-phosphatidylcholines +PIS m/z 184.1 182 
a Fragments released during CID of TAG-ammonium adducts selected for MPIS 
b Fragments released during CID of DAG-ammonium adducts selected for MPIS  
c Fatty acid fragments released from PC-acetate adducts selected for MPIS 
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Elucidation of double bond positions 
As described above, information about the distribution of molecular lipids within a 
specific lipid class can readably be attained by shotgun lipidomics in combination 
with methods such as precursor ion- and neutral loss scanning. However, in most 
cases, conventional CID of lipids does not provide information about the position 
of existing double bonds. Therefore, when using this approach molecular lipids 
that differ only in the position of a double bond are indistinguishable 217-218. 
Several mass spectrometric methods for elucidation of double bond positions have 
been demonstrated. However, many of them require derivatization 219, sufficient 
volatility of the analyte 220, isolated lipids or simple mixtures 218. To overcome 
these limitations a new method based on the shotgun approach has been 
developed, whereby lipids are exposed to ozone vapor within an ion-trap mass 
spectrometer 221. This induces ozonolysis at the position of the double bond, 
producing fragment ions with mass-to-charge ratios specific to the position of the 
double bond. Using this technique, termed ozone induced dissociation (OzID), in 
combination with normal CID, information about both fatty acid positions and 
double bond position can be attained. This technique was used in paper III for the 
characterization of double bond position in specific triacylglycerol molecular 
species.  
Bioinformatics 
When analyzing biological material with a lipidomics approach, it is not unusual 
to obtain data for several hundred, or even thousands, of molecular lipids. As a 
consequence, tools for handling and interpreting this data become a necessity to 
be able to take full advantage of the wealth of new information 222. This field of 
bioinformatics plays important roles in several steps of the post-analytical 
evaluation of the data. The first step is to create lipid databases and methods for 
automated data processing. Or in other words, to convert raw-data files from the 
instrument into final lipid datasets. There are several software packages 
available for this. LipidView™ is registered by Applied Biosystems for use on data 
generated by their mass spectrometers. This software is an extension of the 
prototype LipidProfiler™, for which the details were published a couple of years 
ago 181. There is other dedicated lipid softwares 223-224, and several of the 
common metabolomics data processing tools may also be used in lipidomics. 
Particularly MZmine 225 and XCMS 226, which are both open-source softwares, 
have been broadly applied.  
Following the raw data processing and the generation of lipid datasets, additional 
tools are required for the statistical analysis and interpretation. Commonly used 
are relatively simple univariate tools such as t-tests, non-parametric Wilcoxon 
test and ANOVAs. These methods consider only one lipid at a time, with the 
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potential drawback of missing important information that might exists in 
complex correlation structures of lipidomics datasets. For these purposes, 
multivariate tools can be used, which include principal component analysis (PCA) 
and hierarchic clustering 222, 227.  
In addition to the statistical tools used for indentifying specific differences 
between groups and finding possible biomarkers, it might be interesting to put 
the observed changes in relation to a biochemical or physiological context. The 
KEGG (http://www.genome.jp/kegg) database is a resource commonly used for 
these purposes and includes a collection of manually drawn pathway maps 
representing current knowledge about molecular interaction and reaction 
networks 228. 
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AIMS 
The overall aim of this thesis was: 
To isolate, and with a lipidomics approach, study atherogenic lipoproteins from 
type 2 diabetic patients in search for disease specific biomarkers that would 
increase our understanding of the disease.    
 
The specific aims of the different studies were: 
I. To develop a method for the isolation of VLDL, LDL and HDL using 
ultracentrifugation at physiological pH and ion strengths.    
II. To identify proatherogenic properties of apoCIII containing LDL 
isolated from subjects with T2D.  
III. To investigate whether dyslipidemia is required on top of insulin 
resistance to induce the compositional changes in lipoprotein lipids 
often associated with T2D.    
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RESULTS AND DISCUSSION 
Paper I 
In this paper a new method for isolating lipoproteins, using sequential 
ultracentrifugation, is described.  
Preparation of lipoproteins using ultracentrifugation dates back to the mid 50s 
229-230, and is still one of the most commonly applied methods. Traditionally 
potassium bromide (KBr) is used for density-adjustments during the 
ultracentrifugation procedure. However, the use of high amounts of KBr results in 
a supraphysiological ion strength, which might disrupt the binding of 
exchangeable apolipoproteins attached to surface of the lipoprotein particles 231-
232. Therefore, when studying apolipoproteins such as apoCIII and apoE, which 
are suggested to be important in the pathogenesis of cardiovascular disease, it is 
possible that ultracentrifugation using solutions with high ion strength introduce 
artifacts that might attenuate the importance of these proteins in the etiology of 
the disease. Therefore, the method developed uses a combination of D2O/sucrose 
to acquire the densities necessary for isolation of VLDL, LDL and HDL, which 
occurs at physiological pH and ion strength. This method is an extension of a 
previous method for isolation of LDL using D2O 233.  
The purity of the lipoprotein fractions was tested using a combination of native 
and SDS gel electrophoresis. No contaminations of LDL or albumin were detected 
in the HDL fractions isolated with the two methods (figure 2 and 3, paper I).     
Next the proteins were analyzed using 2D gel electrophoresis. The results 
revealed no significant differences between the VLDL fractions isolated with the 
two methods. For LDL and HDL on the other hand, the 2D gels containing 
D2O/sucrose-isolated proteins showed more intense spots for several of the 
proteins. MALDI-TOF MS revealed that many of them were isoforms of α-1 anti-
trypsin, apoE, apoCII and apoCIII (figure 4 and 5, paper I). 
Results from the SELDI-TOF analysis further strengthen these results as the 
spectra from the D2O/sucrose-isolated LDL and HDL show additional and more 
intense peaks both in the LDL and HDL fractions. Also in this case, the amounts of 
apoCII and apoCIII isoforms (m/z ~ 9000) were significantly different between 
the two methods (figure 6 and 7, paper I).  
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The major lipid classes (cholesteryl esters, triacylglycerols, free cholesterol and 
phosphatidylcholine) in the isolated lipoprotein fractions were quantified using 
normal-phase HPLC with ELS detection. No differences were observed between 
the two methods (figure 8, paper I). This confirmed that the two methods 
separate very similar density ranges of the lipoprotein spectrum. We did not 
investigate the effect of the method on chemically fragile lipids. One has to 
consider the possibility that the use of 30 degrees for the isolation of HDL, which 
is necessary due to the high viscosity of the solutions, might induce auto-
oxidative and enzyme-mediated modifications of lipids containing poly-
unsaturated fatty acids (e.g. linoleic- and arachidonic acid). 
When using KBr for density adjustments, it is required that the isolated 
lipoprotein fractions are dialyzed prior to proteomics or cell experiments. An 
advantage of the described method is that the isolated lipoprotein fractions might 
be used directly without desalting. Furthermore, sucrose improves 
cryopreservation of the biological and physic-chemical integrity of the 
lipoproteins 234. A limitation of the method is that only the major lipoprotein 
fractions are isolated. No isolation of LDL and HDL subclasses is achieved. 
 
Paper II 
In this paper we wanted to identify molecular mechanisms explaining the pro-
atherogenic role of apoCIII in T2D subjects. 
A mechanism possibly involved in the increased atherogenicity of apoCIII-
containing LDL is an increased binding to artery wall proteoglycans 235. To 
investigate this, we incubated apoCIII-rich and apoCIII-poor LDL from T2D 
subjects, with biglycan. Biglycan is considered to be one of the most important 
proteoglycans involved in the retention of lipoproteins in human arteries 36, 134-
135. The results showed that apoCIII-rich LDL had a higher affinity for the 
biglycan. However, complementary experiments with LDL, enriched with apoCIII 
in vitro, showed that this increase could only partly be explained by the apoCIII 
per se (figure 1A, paper II).  These complementary experiments also showed that 
the proteoglycan binding was not linearly correlated to the amount of apoCIII 
molecules on the LDL particle. Whereas moderate levels increased the binding, 
supraphysiological levels of LDL-apoCIII actually inhibited biglycan binding 
(figure 1B, paper II). By performing the same experiment using recombinant 
LDL isolated from apoB transgenic mice, we could also show that the binding was 
mediated by the site A (residues 3148-3158) in the apoB molecule.  
During the binding experiments described above, we concluded that although 
apoCIII per se did induce a small increase in biglycan binding, other intrinsic 
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properties have to be involved to fully explain the increased binding of LDL with 
an endogenously high apoCIII/apoB ratio. Therefore we performed a detailed 
lipid characterization of LDL isolated from T2D and control subjects. The results 
revealed that T2D subjects had reduced amounts of the membrane lipids free 
cholesterol, sphingomyelin, ceramide and the ganglioside GM1, compared to the 
control subjects (figure 2, paper II). We also showed that, only in the T2D 
subjects, where the amounts of these lipids negatively correlated to the 
apoCIII/apoB molar ratio. Furthermore, since the level of the most abundant 
membrane lipid, phosphatidylcholine, was unchanged, these results suggest that 
LDL isolated from T2D subjects has an altered lipid composition.  
Free cholesterol, sphingomyelin and ceramide have all been shown to increase 
membrane rigidity 236-237. Therefore, we suggest that the relative reduction in 
these lipids compared to phosphatidylcholine will result in an increased 
membrane fluidity, which will allow apoB to acquire a conformation that is more 
favorable for proteoglycan binding. In addition, reduced sphingomyelin levels 
might also increase the susceptibility of the LDL particle to hydrolysis by group 
IIA and group V sPLA2 238, two enzymes known to promote atherosclerosis 141, 239. 
It is not known whether the high apoCIII levels modulate the membrane 
composition, or if the increased fluidity of diabetic LDL simply allows more 
apoCIII to bind. However, it has been suggested that apoCIII can activate 
sphingomyelinase 240, which is responsible for the hydrolytic conversion of 
sphingomyelin into ceramide. Increased ceramide content has been shown to 
induce particle aggregation, which is an important event in the pathogenesis of 
atherosclerosis 241. We therefore analyzed the kinetics of sphingomyelinase-
induced hydrolysis of LDL and the kinetics of particle aggregation. We showed 
that for LDL isolated from T2D subjects, enrichment with apoCIII in vitro 
increased the susceptibility of hydrolysis and aggregation by SMase (figure 5, 
paper II). Furthermore, it has been shown that the ganglioside GM1 is an 
inhibitor of SMase 242. Since our results show that LDL isolated from T2D subjects 
has reduced levels of GM1, this could make them even more susceptible for SMase 
hydrolysis. 
We then investigated the relative abundance of the different apoCIII isoforms. 
ApoCIII exists in three isoforms (apoCIII0, apoCIII1 and apoCIII2) differing in the 
number of sialic acids bound to the protein 63. We analyzed the distribution of 
different isoforms on LDL isolated from control subjects and subjects with T2D. 
For both groups, the results showed a positive correlation between the 
apoCIII/apoB ratio and the degree of sialylation. Furthermore, for all 
apoCIII/apoB ratios the T2D subjects had higher levels of the more sialylated 
form (figure 6, paper II).  
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Finally, in a cell experiment using human aortic endothelial cells (HAECs), we 
showed that increased apoCIII sialylation results in increased secretion of the 
proinflammatory mediators Il-6, Il-8, TNF-α and ICAM-1 (figure 7, paper II).  
Taken together, the results from paper II highlights several important properties 
of apoCIII-containing LDL that adds to our understanding of its role in the 
pathogenesis of atherosclerosis. 
 
Paper III  
In this paper we wanted to investigate whether dyslipidemia is required on top of 
insulin resistance to induce the compositional changes in lipoprotein lipids often 
associated with T2D. 
Dyslipidemia, a state of high triacylglycerols and low HDL, is often associated 
with T2D. This makes it hard to determine whether the changes in lipoprotein 
lipid composition often observed in T2D subjects are the result of the 
dyslipidemia or the insulin resistance per se. For example, in paper II we saw 
several changes in LDL isolated from T2D subjects. However, many of these 
subjects also had dyslipidemia (table S3, paper II). In an attempt to clarify the 
role of dyslipidemia versus insulin resistance for lipoprotein modification, VLDL 
and LDL from T2D subjects, with and without dyslipidemia, were characterized.     
The lipid class composition of VLDL and LDL isolated from normolipidemic T2D 
subjects was very similar to control subjects (figure 1, paper III). The only 
difference was a slight decrease in lyso-phosphatidylcholine in LDL. The 
dyslipidemic T2D subjects, on the other hand, showed more pronounced 
differences with increased triacyl- and diacylglycerol together with reduced 
sphingomyelin in VLDL. In LDL there was an increase in diacylglycerol, while 
cholesteryl ester, ceramides, sphingomyelin and free cholesterol were reduced 
(figure 1, paper III). Phosphatidylcholine were not reduced resulting in an 
altered membrane composition similar to what we saw in paper II.  
A closer investigation of the lipid species within each lipid class revealed that 
both T2D groups contained increased amount of PC 16:0-20:3 and PC 18:0-20:3 
(figure 2, paper III). In the dyslipidemic group, PC 16:0-16:1 was also increased 
together with increased amount (both absolute and relative) of CE 20:3 and CE 
16:1. Furthermore, the amount of C16:1 and C20:3 correlated extremely well 
between the two lipid classes, indicating that these two lipid classes are 
metabolically linked through the lecithin-cholesterol acyltransferase (LCAT). In 
the circulation, this enzyme is responsible for transesterification of cholesterol 
with the fatty acid from the sn-2 position of phospholipids 243. It has been shown 
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previously that these fatty acids (C16:1 and C20:3), at least when hydrolyzed to 
phosphatidylcholines and cholesteryl esters, are related to T2D 244-245. A possible 
explanation for this might be that the hyperinsulinemia in these subjects induces 
the expression of SREBP1c 246-247. This in turn leads to the activation of Δ9 and Δ6 
desaturases, which might result in an increased amount of C16:1 and C20:3 in 
both cholesteryl ester and phosphatidylcholine lipid classes 245, 248-249. 
Since it has been shown that dyslipidemia is linked to an increased VLDL 
secretion and de novo lipogenesis, we hypothesized that this would induce an 
altered fatty acid composition of the VLDL triacylglycerols from the dyslipidemic 
subjects. Initially the fatty acid composition was measured as methyl esters with 
GC/flame ionization detector (FID). This showed an increased absolute and 
relative amount of palmitic acid in the dyslipidemic group, suggesting increased 
lipogenesis 250. Further characterization of both the triacylglycerols and the 
diacylglycerols using multiple PIS identified several, specific  lipid species 
containing palmitic acid that were elevated in the group with dyslipidemia 
(figure 4, paper III). The most prominent were TAG 16:0/16:0/16:0, TAG 16:0-
16:0-18:1 and TAG 16:0-16:0-16:1. Similar patterns were observed in the 
diacylglycerols with DAG 16:0-16:0 and DAG 16:0-16:1 being significantly 
increased. From the raw data acquired during PIS, a fatty acid profile very similar 
to the one obtained from the GC/FID could be created (figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Fatty acid profile of VLDL triacylglycerols attained by (A) GC/FID or (B) QqTOF MS. 
For abbreviations and group characteristics, see methods in paper III.    
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Next we tested whether the significantly altered lipid species correlated with 
important clinical parameters such as BMI or HOMA index (table 2 and 3, paper 
III). Several of the cholesteryl ester and phosphatidylcholine species correlated 
well with many of the measured parameters, with PC 18:0-20:3 showing the 
strongest correlation. Kotronen et al. have recently shown that serum 
triacylglycerols, containing saturated fatty acids, are better markers of insulin 
resistance than total serum triacylglycerol concentration 251. Our results show 
that several of the palmitate-containing triacylglycerols, especially  TAG 16:0-
16:0-18:1, correlate positively with insulin resistance. However, all correlations 
were weaker than correlations with total plasma triacylglycerols.  
An increase in de novo lipogenesis would result in an increased production of 
palmitic acid. This will in turn activate desaturases perhaps in an attempt to 
transform the palmitic acid into the less toxic palmitoleic acid 252. An increase in 
palmitoleic acids was seen both in the phosphatidylcholine and cholesteryl ester 
lipid class in the subjects with dyslipidemia. Furthermore, data from the GC/FID 
analysis showed that it was also increased in the VLDL triacylglycerols with 
borderline significance (p=0.05). Further metabolism of the palmitoleic acid into 
vaccenic acid (C18:1 n-7) is possible by Elovl5-mediated elongation 253. However, 
analysis using the QqTOF instrument does not allow the determination of double 
bond position. Furthermore, vaccenic acid was not included in the standard 
mixture used for GC/FID analysis. To elucidate whether the increased abundance 
of palmitic acid results in increased amounts of vaccenic acid we used the novel 
OzID methodology 218, 221. This allows the assignment of both the position (sn-1(3) 
or sn-2) of the fatty acids on the glycerol backbone and the double bond position 
of each fatty acid. By utilizing this methodology, the TAG 50:1 (50 carbons and 1 
double bond in total on the three fatty acids) was characterized. The results 
revealed several findings. First, the TAG 50:1 almost exclusively consisted of the 
TAG 16:0-16:0-18:1. Secondly, the isomer TAG 16:0/18:1/16:0 was increased by 
about 10% in the two groups with T2D subjects (figure 5, paper III). Finally, in 
the dyslipidemic group, there was an increase in the abundance of vaccenic acid 
incorporated at the sn-2 position (figure 6, paper III).  
It has previously been shown that VLDL, and especially VLDL from 
hypertriglyceridemic subjects, induces a pro-inflammatory response in cultured 
endothelial cells 254-255. Even though it has been suggested that the composition of 
the particle is responsible for the induced response, the actual mechanisms are 
poorly understood. We wanted to test the hypothesis that the increased response, 
of VLDL from hypertriglyceridemic subjects, could be a result of increased 
palmitate in the VLDL triacylglycerols. We therefore incubated smooth muscle 
cells and endothelial cells with isolated VLDL containing high and low 
triacylglycerol palmitate (38±0.2% and 26±0.9% respectively). The result 
showed a highly significant increase in the secretion of several cytokines from the 
cells incubated with VLDL with high levels of palmitate. We cannot from these 
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results exclude the possibility that other intrinsic properties, such as protein 
composition or state of oxidation, could induce the observed response. However, 
there were no significant differences in any of the other measured lipid classes 
between the two groups.  
In conclusion, VLDL and LDL from normolipidemic T2D subjects display some but 
rather modest changes in lipid composition compared to VLDL and LDL isolated 
from control subjects. In contrast, both lipoproteins display significant changes in 
dyslipidemic T2D subjects. Some of these are associated with inflammatory 
properties.  
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CONCLUDING REMARKS 
In theory, the solution to the world epidemic of obesity and T2D is rather simple. 
It is all about reducing the energy intake and increasing the energy expenditure. 
In other words: eat less, exercise more. However, it is naive to believe that these 
recommendations would change the behavior of millions of people now 
accustomed to a sedentary lifestyle and quick access to palatable energy-dense 
food. Instead we are relying on the pharmaceutical and nutritional industries to 
provide alternative ways of relieving the burden. So in order to improve 
prevention and treatment of cardiovascular disease, which is often the cause of 
death in patients with obesity and T2D, a detailed understanding of the 
pathogenesis of atherosclerosis is needed. In the work included in this thesis the 
focus has been on dyslipidemia, which is a cardinal feature of both obesity and 
T2D. More specifically we wanted to link compositional changes in VLDL and LDL 
to the increased atherogenicity of these lipoproteins in patients with T2D. In 
order to do this, a lipidomics approach was used.  
From our results we can conclude that both the protein and lipid composition of 
the particles are important for the increased atherogenicity. In paper II we see 
that apoCIII, which is a protein that has recently been recognized as a 
cardiovascular risk factor, is increased on LDL particles isolated from T2D 
subjects. In the paper we show that this is associated with increased binding of 
LDL to artery wall proteoglycans and increased susceptibility of the particle to 
SMase that drives the production of ceramides. Both are important events in the 
atherosclerotic process. We could also show that the sialylation of apoCIII is 
important for mediating an inflammatory response in cultured HAEC cells. 
However, the metabolism of apoCIII is complex and additional studies are needed 
to further clarify the role of apoCIII in atherosclerosis. Possible strategies would 
be to use tracer methods, possibly combined with immunoaffinity 
chromatography 125-126.    
In both paper II and paper III we showed that VLDL and LDL isolated from T2D 
subjects with dyslipidemia had an altered lipid composition compared to the 
control subjects. We believe that this alteration is affecting the conformation of 
the apoB molecule making the particle more susceptible for proteoglycan 
interaction. However, the exact mechanism for the alteration in lipid composition 
remains to be determined.   
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The lipidomics analysis of VLDL and LDL, performed in paper III, revealed 
several interesting alterations occurring at the molecular level in the subjects 
with dyslipidemia. The amount of C16:1 and C20:3 were increased in several lipid 
classes, indicating alterations in desaturase activity. Furthermore, VLDL 
triacylglycerols were enriched in palmitate that induced a highly 
proinflammatory response when incubated with endothelial and smooth muscle 
cells. 
By using the novel OzID-technique we took a step further towards the full 
characterization of lipoprotein lipids and showed that alterations might occur 
even at the level of double bond position. This highlights the importance of 
having powerful tools for indentifying potential biomarkers and to fully elucidate 
the mechanisms that are important in generating the atherogenic lipoproteins 
observed in patients with T2D. 
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LIPIDOMICS PERSPECTIVE 
Although still in its infancy, lipidomics has already positioned itself as an 
important tool in biological research. The development of advanced mass 
spectrometric equipment in combination with selective fragmentation 
techniques, such as OzID, now enables us to reach far into the lipidome and 
acquire information about low abundant and structurally specific lipids. These 
tools will become crucial for further our understanding of how the molecular 
composition of the cellular lipidome affects important functions and maintains 
cell homeostasis. An example highlighting the importance of determining the 
molecular lipids was shown a few years back when Shinzawa-Itoh et al. showed 
that a specific phosphatidylglycerol molecule containing palmitic acid (on the sn-
1 position) and vaccenic acid (on the sn-2 position) was needed for normal 
function of cytochrome c oxidase 256. Another example has been shown for the 
survival of C. elegans exposed to anoxia. Specific molecular sphingolipids 
containing C24 and C26 carbons were associated with death, while molecular 
lipids with shorter chains were involved in survival 257. In fact, researchers in the 
field of sphingolipids are probably one of the groups that will benefit the most 
from the advances in MS. So far, a comprehensive characterization of this group 
of highly interesting and multifaceted group of lipids has been limited due to the 
structural complexity of the lipid class and the lack of analytical power 156, 258. 
Hence, as the field of lipidomics progresses we can expect many interesting 
discoveries in this field in the years to come 
Despite predictions of future success, one has to remember that lipidomics is not 
just chemistry alone. It’s becoming increasingly clear that just measuring 
hundreds, or even thousands, of lipids within a cell might not be that informative, 
unless we can localize the lipids to the subcellular compartments 258-259. This 
means that either we find efficient ways of isolating the sub-cellular 
compartments or we develop imaging techniques with subcellular resolution. At 
the moment TOF-SIMS can reach nanometer-scale resolution but suffers from 
problems with relatively low sensitivity and extensive fragmentation during the 
ionization process. However, if new instruments can be developed where these 
issues have been resolved, this technique has great potential of becoming an 
important complement in the analytical toolbox within the field of lipidomics.  
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Another aspect that needs to be considered, when charting the abundance of 
hundreds of molecular lipids, is that the concentration of certain lipids is highly 
dynamic, changing rapidly within several orders of magnitude during certain 
stimuli. However, what is often the result of an experiment is a snapshot of the 
biological tissue, cell or biofluid that is being investigated. Therefore, important 
information about kinetic parameters and fluxes within the biological system will 
be overlooked. An interesting way to unravel these questions might be to use 
tracer lipidomics, which is a branch of lipidomics in where labeled lipids (often 
with stable isotopes) are followed during time.  
Even though it is clear that lipidomics can add another dimension to our 
understanding of common diseases, it remains to be seen whether it will take the 
step into a more clinical setting. If it did, it would probably open up new sources 
of information as lipidomics screens of patients are likely to give a wider 
understanding how specific diseases will cause “ripple effects” through the 
lipidome 260. Also in the pharmaceutical industry lipidomics might have a place 
both in preclinical and clinical settings. To this end, lipidomics has been shown to 
provide information about efficacy profiles of different compounds within a 
specific drug class 261-262 in addition to functioning as a tool for identifying 
adverse drug effects, such as muscle and liver toxicity 261, 263. It is also tempting to 
believe that in the era of personalized medicine, it could provide useful 
information during clinical trials about responders and non-responders.  
To conclude, since lipids play important roles in a vast number of cellular 
processes and the fact that dysregulation of lipid metabolism is associated with 
many different and severe diseases, it is not bold to predict that lipidomics will 
continue to be a major resource in many scientific and medical fields in the years 
to come. 
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